ENHERTU gets FDA priority review in HER2-positive metastatic gastric cancer

This article was originally published here

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious

The post ENHERTU gets FDA priority review in HER2-positive metastatic gastric cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply